Moreover, pharmacological inhibition of ROS accumulation was sufficient to rescue the aberrant viability phenotype in podocytes with reduced functional clavesin-1, revealing new possible therapeutic strategies for patients with NS due to CLVS1 defects and a possible adjunct therapy for children with the more common idiopathic NS. The gene discussed is CLVS1; the disease is Netherton syndrome.